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BACKGROUND: Congenital infection with human cytomegalovirus RESULTS: At the interim analysis, 8 of 11 women delivered an
is a major cause of morbidity and mortality. A randomized controlled
trial showed that high-dosage valacyclovir prevents cytomegalovirus
disease in transplant recipients. Fetuses showing ultrasound features
of infection are at high risk of being symptomatic at or before birth.
In a pilot study, oral administration of high-dosage valacyclovir to
mothers significantly decreased viral load and produced therapeutic
concentrations in the blood of infected fetuses. A randomized
controlled trial comparing prenatal treatment with valacyclovir against
placebo in infected fetuses failed to recruit because women declined
randomization. Randomized controlled trials in fetal medicine have
often proven unacceptable by women who decline termination of
pregnancy and are not prepared to resign themselves to the odds of
the natural history of the disease.
OBJECTIVE:We evaluated the efficacy of oral valacyclovir, 8 g daily, for
pregnant women carrying a symptomatic cytomegalovirus-infected fetus,
targeting a high-risk group for developing both neurosensory and neuro-
logical impairment.
STUDY DESIGN: We designed a multicenter, open-label, phase II
study with 1 arm, using one of Simon’s optimal 2-stage designs. Symp-
tomatic fetuses were defined by the presence of measurable extracerebral
or mild cerebral ultrasound symptoms. They were treated in utero from
prenatal diagnosis at a median of 25.9 weeks’ gestation until delivery or
termination of pregnancy. Fetuses with severe brain anomalies on ultra-
sound were not included as were cases completely asymptomatic at
presentation, because treatment was unlikely to modify either outcome.
The primary endpoint was the proportion of asymptomatic neonates born
to treated mothers.Cite this article as: Leruez-Ville M, Ghout I, Bussie`res L,
et al. In utero treatment of congenital cytomegalovirus
infection with valacyclovir in a multicenter, open-label,
phase II study. Am J Obstet Gynecol 2016;215:
462.e1-10.
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462.e1 American Journal of Obstetrics& Gynecology OCTOBER 2016asymptomatic neonate (required:7). In step 2, 32 additional cases were
included for a total of 43; the final number of asymptomatic neonates was
34, more than the 31 required to indicate efficacy according to the Simon
2-stage design. They remained asymptomatic at 12 months. High-dosage
valacyclovir given for a median of 89 days to pregnant women carrying a
moderately infected fetus was efficient at giving birth to asymptomatic
neonates. Fetal blood viral loads decreased and platelet counts increased,
both significantly (P¼ .01 and P< .001, respectively), between treatment
initiation and birth after treatment completion, regardless of duration of
fetal infection. Compared with a historical cohort obtained by a meta-
analysis of the literature, the use of valacyclovir (8 g daily) significantly
increased the proportion of asymptomatic neonates from 43% without
treatment to 82% with treatment. Although the pill burden was high
(16 pills a day) adherence to treatment was>90%. Finally, valacyclovir at
this high dosage was extremely well tolerated.
CONCLUSION: Our results indicate that high-dosage valacyclovir
given in pregnancy is effective for improving the outcome of moderately
symptomatic infected fetuses. Although this study is not a randomized
controlled trial, this is the first study reporting the efficacy of an antiviral
drug to treat cytomegalovirus-infected fetuses. Moreover, this first study
will allow new trials to be conducted, using valacyclovir as a baseline safe
and effective treatment in pregnancy, to be compared to the new emerging
and more potent anticytomegalovirus drugs that have not currently been
tested in pregnancy.
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Congenital cytomegalovirus (CMV)
infection affects 0.7% of live births and is
the leading cause of congenital neuro-
logical disease of infectious origin.1
Among all neonates positive for infec-
tion on screening, 20% eventually have
neurodevelopmental impairment with
permanent sequelae.2 Around 10% of
infected neonates are symptomatic at
birth; their risk of sequelae reaches 58%,
including sensorineural hearing loss orcognitive or motor defects. The risk of
sequelae in newborns who were asymp-
tomatic at birth is around 13%, mainly
due to progressive hearing loss.2
An infected fetus’s risk of symptoms
at birth is assessed by interpreting the
results of both prenatal imaging and
laboratory tests.3-8 Fetal CMV disease is
progressive: early symptoms of systemic
infection can be expressed as extracere-
bral ﬁndings at prenatal ultrasound; fetal
brain involvement usually does not show
TABLE 1
Main inclusion criteria
At least 1 extracerebral abnormality
compatible with fetal CMV infection
Fetal growth restriction42
Abnormal amniotic fluid volume
Ascites and/or pleural effusion
Skin edema
Hydrops
Placentomegaly >40 mm43
Hyperechogenic bowela
Hepatomegaly >40 mm44
Splenomegaly >30 mm45
Liver calcifications
And/or 1 isolated cerebral abnormality
Moderate isolated ventriculomegaly (<15 mm)
Isolated cerebral calcification
Isolated intraventricular adhesion
Vasculopathy of lenticulostriate vessels
And/or laboratory findings of generalized
CMV infection in fetal blood
Fetal viremia >3000 copies/mL
Fetal platelet count <100,000/mm3
All ultrasound examinations leading to inclusion in study were reviewed by principal investigator at each center. Measurements
of spleen, liver, and placenta were standardized according to literature.43-45
CMV, cytomegalovirus.
a Since diagnosis of hyperechogenic bowel can be subjective and associated with high interoberver and intraobserver
variability, diagnosis of hyperechogenic bowel was only considered for grade-2 or grade-3 hyperechogenic bowel46; this
semiquantitative analysis was chosen to limit subjectivity sometimes associated with ultrasound findings.
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lesions seen on prenatal ultrasound
predict a dismal outcome.4 This leaves a
window of opportunity for treatment
of symptomatic fetuses without brain
involvement.10
Vaccination is not available11 and
no prenatal treatment of congenital
CMV has yet been validated. The use of
CMV-speciﬁc hyperimmune globulin
to prevent transmission from mother
to fetus has produced conﬂicting re-
sults.12,13 Neonatal antiviral treatment
with either ganciclovir or valganciclovir
improves auditory and neurological
outcomes in symptomatic newborns,14
but these drugs, highly genotoxic
in vitro, are not approved in pregnancy.
Although valacyclovir is less effectivethan ganciclovir against CMV in vitro,15
high-dosage valacyclovir has proven
clinically efﬁcient to prevent CMV
disease in transplant recipients.16 The
mechanism of acyclovir’s anti-CMV
activity in clinical settings remains un-
explained. Valacyclovir also has the best
safety proﬁle of the anti-CMV drugs.
Neither cell transformation nor
increased risk of neoplasia has been re-
ported in vitro, and no increased risk of
birth defects has been detected in
the offspring of thousands of women
exposed during pregnancy.17,18 Finally,
valacyclovir is well tolerated with rare
side effects. In a pilot study, we found
that oral administration of high-dosage
valacyclovir to mothers signiﬁcantly
decreased viral load and producedOCTOBER 2016 Ameritherapeutic concentrations in fetal blood
with a mean fetal blood plasma con-
centration of >17 mmol/L. These results
suggested the value of a clinical trial
to investigate this therapeutic option
further.10 We failed to complete a ran-
domized controlled trial comparing
prenatal treatment with valacyclovir
against placebo in moderately symp-
tomatic infected fetuses due to failure to
recruit (Cymeval NCT01037712). In this
open-label phase II trial with 1 arm we
show that high-dosage valacyclovir given
in pregnancy is safe and appears effective
for improving the outcome of moder-
ately symptomatic fetuses.
Materials and Methods
Patients
Eligible women were pregnant with an
infected fetus identiﬁed by a positive
CMV polymerase chain reaction assay in
amnioticﬂuid, sampled by amniocentesis
>21 weeks,19-22 together with the pres-
ence of 1 extracerebral ultrasound
features compatible with CMV infection
and/or 1 isolated cerebral abnormality
and/or 1 of the following laboratory
ﬁndings in fetal blood: fetal platelet count
<100,000/mm3 or CMV DNA viral load
>3000 copies/mL (Table 1). The presence
of severe ultrasound brain abnormalities
(Table 2) and the absence of any ultra-
sound feature of infection or laboratory
abnormality in fetal blood were exclusion
criteria. Thedetailed eligibility criteria are
listed in the supplementary Appendix.
Fetal blood sampling by cordocentesis
under ultrasound guidance was offered to
all participants to evaluate fetal platelets
and viral DNA load to help reﬁne the
fetal prognosis.4 Cordocentesis was not,
however, required for study eligibility, as
this invasive procedure was not the stan-
dard of care in all participating centers.
Procedures
Study design
The trial was a multicenter, open-label,
phase II study with 1 arm, based on 1 of
Simon’s23 optimal 2-stage designs. All
participants received oral valacyclovir
(2 g, 4 times a day, therefore 8 g daily).
The medication was continued until
delivery or 24 treatment weeks, which-
ever was sooner. The study drug wascan Journal of Obstetrics& Gynecology 462.e2
TABLE 2
Main exclusion criteria
Presence of at least 1 severe cerebral ultrasound
abnormality among following:
Ventriculomegaly 15 mm
Periventricular hyperechogenicity
Hydrocephaly
Microcephaly <3 SD
Mega-cisterna magna >10 mm
Vermian hypoplasia
Porencephaly
Lissencephaly
Periventricular cysts
Abnormal corpus callosum
Or absence of any ultrasound feature of infection
or laboratory abnormality in fetal blood
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Le Roi, France), which had no other role
in the study. Visits for clinical and ultra-
sound examinations, questions about
clinical side effects (headache, nausea,
neurologic effects listed in the product
monograph), and adherence assessment
by pill count were scheduled every 2
weeks until delivery. Maternal plasma
levels of aspartate aminotransferase,
alanine aminotransferase, and creatinine
were assessed once a month during
treatment. All newborns were examined
between days 4 and 7 of life by a trained
pediatrician according to a standardized
clinical evaluation. Auditory brainstem
responses, cranial ultrasound, fundo-
scopy, and laboratory tests (see criteria
for primary endpoint in supplementary
data) were also performed.
The ethics committee of Poissy-Saint
Germain Hospital approved the study
(2011-001610-34). Participants gave
written informed consent before inclu-
sion. Study oversight was provided by an
independent data and safety monitoring
board (Clinical Research Unit, Cochin-
Necker, Paris).
Study endpoints
The primary study endpoint was the
proportion of asymptomatic neonates
born to women treated with valacyclovir.
An asymptomatic neonate was a neonate
without growth restriction (that is, with
birthweight 10th percentile), normal
clinical examination, normal laboratory
ﬁndings, no severe features of infection
on cerebral imaging, normal fundu-
scopic examination, and normal audi-
ology ﬁndings (see the supplementary
Appendix for details).
The secondary endpoints included
adverse events related to the study medi-
cation and adherence to treatment. CMV
DNA levels and platelet counts were
compared in pretreatment fetal blood
when available and cord blood at birth
and in symptomatic and asymptomatic
neonates. The effect of the duration of
maternal treatment was also assessed.
Historical comparator group
Our systematic review on PubMed
using 3 key words (“cytomegalovirus,”
“congenital,” “ultrasound”) yielded 216462.e3 American Journal of Obstetrics& Gynecolarticles, but only 3 were written in
English and included detailed tables that
described both prenatal ultrasound
ﬁndings and neonatal outcome and also
included postmortem ﬁndings in termi-
nation of pregnancy cases.10,24,25 These 3
suitable studies included 724 pregnancies
with a maternal CMV primary infection,
217 with an infected fetus. The review
of the ultrasound symptoms of these
217 fetuses showed no ultrasound ab-
normalities in 142 of them and severe
cerebral ultrasound abnormalities in 28.
Ultrasound abnormalities matching our
inclusion criteria were therefore seen in
47 cases, which formed the historical
comparator group. Among them 20
(42.55%) neonates were born asymp-
tomatic. Twenty fetuses were terminated
and all underwent postmortem exami-
nation showing both macroscopic and
microscopic evidence of brain damage
in all cases. We therefore assumed that
these fetuses would have been born
symptomatic and classiﬁed then into the
symptomatic group. See Table S1 for
details in the supplementary Appendix.
Laboratory assays
CMV serology and viral load quantiﬁ-
cation were centralized and analyzed at
the Necker Hospital virology laboratory.
Maternal CMV primary infection wasogy OCTOBER 2016diagnosed by seroconversion or the
concomitant presence of CMV-speciﬁc
IgM antibodies and low IgG avidity.22
After extracting DNA from fetal whole
blood, cord whole blood, and neonatal
urine with the MagnaPure LC platform
(Roche Diagnostic, Meylan, France), we
performed quantitative polymerase
chain reaction for CMVwith the CMV-R
gene kit (Argene, BioMerieux, Marcy-
L’Etoile, France). The limit of detection
was 446 copies (or 178 IU)/mL.
Statistical analysis
To estimate the sample size according
to Simon23 optimal 2-stage design, we
assumed that a proportion of asymp-
tomatic neonates of <60% was not
clinically relevant in relation to valacy-
clovir efﬁcacy, while a proportion of
>80% was deemed acceptable. With a
type I error ﬁxed at 0.05 and a power of
80%, we needed 11 infected fetuses for
the ﬁrst stage: if at least 8 cases in stage 1
had a good outcome (were asymptom-
atic), then 32 additional infected fetuses
would be included in stage 2 for a total
of 43. If at least 31 of the 43 cases
were asymptomatic at birth, valacyclovir
would be judged to have a positive effect.
Analyses of efﬁcacy data were
performed for all included fetuses
(intention to treat). The proportion of
FIGURE 1
Flowchart of enrollment and outcomes
Enrollment and outcomes.
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conﬁdence interval were calculated with
an unbiased estimator.26 In the historical
comparator group, we used a random
effects model to calculate the overall
proportion of asymptomatic neonates
and a 95% conﬁdence interval for all
47 cases from the 3 studies.
We used nonparametric tests for all
secondary analyses.Platelet counts at birth and in fetal
blood were compared to the gestational
age-speciﬁc reference range published by
Meher-Homji et al.27 The average indi-
vidual deviations of values at birth and in
fetal blood from the published mean in
noninfected fetuses were compared to 0.
We also compared individual differences
in platelet counts between fetal blood
and birth to the slope of the referenceOCTOBER 2016 Amerimean in noninfected fetuses. Two-sided
t tests were used for these analyses.
R software (Version 2.15; R Founda-
tion for Statistical Computing, Vienna,
Austria) was used for all statistical
analyses and its “meta” package for the
metaanalysis.
Results
Enrollment and baseline
characteristics
From January 2012 through December
2014, 41 pregnant women and their
43 fetuses (39 singletons and 4 twins
from 2 pairs of dichorionic twins) were
enrolled at 6 centers, as described in
Figure 1. Table 3 summarizes their
baseline characteristics. The median
gestational age at inclusion was 26
(range 22-35) weeks. All but 1 woman
had a primary infection at a median
gestational age of 10 weeks. In all, 54%
of all fetuses presented with at least
2 eligible ultrasound symptoms, 39%
with only 1, and 3 showed only viremia
>3000 copies/mL (4500; 90,000; and
101,000 copies/mL, respectively).
Primary endpoint
At the planned interim analysis, 8 of
the ﬁrst 11 women included had given
birth to an asymptomatic neonate.
This number exceeded the number of
asymptomatic neonates (7) required to
continue to step 2, which included 32
additional fetuses, for a total of 43. The
ﬁnal analysis showed 34 asymptomatic
neonates, more than the 31 required to
suggest efﬁcacy according to the Simon23
optimal 2-stage design in the population
studied (Table 4).
Comparison of results of our trial with
those of the historical cohort indicates
that valacyclovir signiﬁcantly increased
the proportion of asymptomatic neo-
nates, from 43% (range, 29e57) without
treatment to 82% (range, 67e88) with
treatment (and without any overlapping
of conﬁdence intervals) (Figure 2).
The 9 symptomatic cases include 2
terminations of pregnancy performed
because a severe brain abnormality
subsequently appeared on ultrasound
(Table 5). There was only 1 signiﬁcant
difference in maternal and fetal charac-
teristics at baseline (Table 6a, 6b)can Journal of Obstetrics& Gynecology 462.e4
TABLE 4
Primary endpoint and efficacy
First step Second step
Outcome no.
Asymptomatic neonates 8 34
Symptomatic neonates or termination of pregnancy 3 9
Total 11 43
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TABLE 3
Characteristics of population at baseline
Characteristics
Median [interquartile
range] or n (%)
Women (N ¼ 41)
Age at inclusion, y 31.2 [28.6e33.9]
Body mass index before pregnancy 21.6 [19.8e23]
Parity
0 11 (26.8)
1 30 (73.2)
No. of pregnancies 2 [2e3]
Primary infectiona 40 (97.6)
Gestational age at primary infection, wk 10 [7.8e16.2]
Gestational age at inclusion, wk 25.9 [24.1e31.7]
Interval between primary infection and inclusion, wk 16 [12.3e18.6]
Fetuses (N ¼ 43)
Only 1 symptom at ultrasound 17 (39.5)
>1 Symptom at ultrasound 23 (53.5)
Fetal blood CMV DNA load >3000 copies/mL 3 (7)
Fetal growth restriction 3 (7)
Abnormal amount of amniotic fluid 3 (7)
Ascites and/or pleural effusion 1 (2.3)
Placentomegaly 13 (30.2)
Hyperechogenic bowel 25 (58.1)
Hepatomegaly 6 (14)
Splenomegaly 9 (20.9)
Liver calcification 1 (2.3)
Moderate cerebral abnormality 5 (11.6)
CMV, cytomegalovirus.
a Forty women had primary infection and 1 woman was diagnosed with secondary infection.
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tomatic neonates) and poor (symptom-
atic neonates or termination of
pregnancy) outcomes: fetal platelet
count at inclusion, which was signiﬁ-
cantly lower in the poor outcome group
(P < .007) (Table 6b). The duration
of maternal treatment did not
differ signiﬁcantly between the 2 groups
(P ¼ .236) (Table 6a).
Table S2 reports all details on preg-
nancy outcome (gestational age at
delivery, birthweight, clinical examina-
tion, imaging, and laboratory data).
Secondary endpoints
Adverse events
Valacyclovir was well tolerated. Only
2 women reported headaches, and treat-
ment was suspended for 10 days in only
1. Although maternal alanine amino-
transferase and aspartate aminotrans-
ferase levels increased after 3 months of
treatment, this increase was not clinically
relevant; all values were <40 IU/L, and
creatinine levels did not change
throughout treatment (Figure S1).
Adherence in the subgroup of 27 women
evaluated for it was >90% (Table S3).
Viral loads and platelet counts
Although the duration of maternal
treatment was not correlated with CMV
DNA levels in either cord blood (P¼.65)
or neonatal urine (P ¼ .24), longer
duration was associated with a higher
platelet count at birth (P ¼ .018)
(Figure S2 and Table S4). Neither viral
loads nor platelet counts at birth were
correlated with the time of maternal
infection in pregnancy and therefore
with the duration of fetal infection
(Table S4). Symptomatic and asymp-
tomatic neonates did not differ signi-
ﬁcantly for viral DNA load levels
in either neonatal cord blood (P ¼ .391)
or neonatal urine (P ¼ .081), but the
neonatal platelet count was signiﬁcantly
lower in symptomatic neonates (P <
.001) (Table S5). Blood viral load
decreased and platelet count increased,
both signiﬁcantly, between the fetal
blood obtained in utero before maternal
treatment began and the cord blood
sampled at birth (P ¼ .01 and P < .001,
respectively) (Table 7). The mean462.e5 American Journal of Obstetrics& Gynecolincrease in platelet counts from the
beginning to the end of valacyclovir
treatment was signiﬁcantly higher thanogy OCTOBER 2016the expected corresponding increase
in noninfected fetuses (P ¼ .008)
(Figure S3).
FIGURE 2
Valacyclovir effect compared to historical control group
Study 
Fixed effect model 
Valaciclovir effect * 
Jacquemard, 200710
Guerra, 200824 
Picone, 200825
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Proportion of asymptomatic neonates and 95% confidence interval (CI) were calculated with un-
biased estimator.26 In historical control group, we used random effects model to calculate overall
proportion of asymptomatic neonates and 95% CI for 43 cases reported in 3 suitable published
studies. *Unbiased estimation of binomial probability in multistage design.
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obviously not completed. They have
currently been followed up for a median
of 12 (range 4-36) months. Among
the 33 children who were asymptomatic
at birth, all were still asymptomatic at
12 months of age. All 7 neonates with
symptoms were treated with valganci-
clovir for 6 weeks and none showed
subsequent worsening of neurosensory
hearing loss.
Historical cohort
Analysis of the historical group showed
that any proportion of asymptomaticTABLE 5
Characteristics of 9 cases with poor ou
Case
Gestational age at
primary infection, wk
Gestational age
at inclusion, wk
1 10 23
2 23
3 13 35
4 9 32
5 9 25
6 6 23
7 7 24
8 8 22
9 Secondary maternal
infection
26
a Two terminated fetuses underwent postmortem examination a
Leruez-Ville et al. In utero treatment of congenital cytomeganeonates <60% would be unacceptable
for Simon23 optimal 2-stage design.
Moreover, comparison of our trial re-
sults with those of the historical cohort
indicates that valacyclovir signiﬁcantly
increased the proportion of asymptom-
atic neonates, from 43% without treat-
ment to 82% with treatment (and
without any overlapping of conﬁdence
intervals) (Figure 2).
Comment
This is the ﬁrst trial of antiviral treatment
of symptomatic fetuses with CMV
disease. This approach followed a pilottcome
Inclusion criteria
D
t
Oligohydramnios, hyperechogenic bowel
Hyperechogenic bowel, intraventricular adhesion
Intraventricular adhesion
Fetal growth restriction placentomegaly,
intraventricular adhesion
Hyperechogenic bowel, fetal thrombocytopenia
(55,000/mm3)
Hyperechogenic bowel
Hyperechogenic bowel, fetal thrombocytopenia
(66,000/mm3)
1
Hyperechogenic bowel
Fetal growth restriction
nd in both cases severe brain lesions were identified.
lovirus infection. Am J Obstet Gynecol 2016.
OCTOBER 2016 Ameristudy conducted from 2003 through
2005 that suggested treatment with high-
dosage valacyclovir given orally to preg-
nant women carrying a symptomatic
fetus infected with CMV could decrease
viral DNA loads and achieve therapeutic
concentrations in fetal blood.10 A phase
II randomized placebo-controlled
trial was planned to test the efﬁcacy of
valacyclovir given to women with a
symptomatic infected fetus (Cymeval
NCT01037712) in 2008. It failed, how-
ever, to recruit enough participants,
including only 6 women over 2 years.
To avoid what appeared to be an unac-
ceptable placebo arm, we shifted to a
trial based on a Simon23 optimal 2-stage
design with only 1 armetreated patients
(Cymeval II NCT01651585). Severe fetal
cerebral lesions are known to have a
dismal prognosis and are unlikely to be
reversible under treatment.28 Their odds
ratio for a poor outcome was 40.64; we
therefore excluded them. Women car-
rying an infected fetus that appeared
completely asymptomatic on ultrasound
and had normal laboratory results
were similarly excluded, because their
outcome is known to be generally
good.4,9,29,30 In a previous study, we
showed that odds ratio for a poor
outcome was 4.4 when there was anyays of
reatment
Symptoms at birth
or termination of pregnancy
92 Bilateral hearing loss
18 Termination of pregnancya
5 Termination of pregnancya
6 Bilateral hearing loss
97 Thrombocytopenia (59,000/mm3)
99 Unilateral hearing loss
03 Unilateral hearing loss
15 Unilateral hearing loss
68 Growth restriction
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TABLE 6
Comparison of maternal and fetal characteristics at baseline between cases with good (asymptomatic neonate)
and poor (symptomatic neonate or termination of pregnancy) outcomes
Table 6a.
Women’s characteristics
Total Good outcome Poor outcome
P
Median [interquartile range] Median [interquartile range] Median [interquartile range]
(N ¼ 41) (N ¼ 33) (N ¼ 8)
Maternal age at inclusion, y 31.2 [28.6e33.9] 31.5 [28.8e33.9] 30.2 [28.1e33.5] .717
Body mass index before pregnancy 21.6 [19.8e23] 20.4 [19.4e22.7] 22.9 [21.8e23.9] .058
Parity, n (%)
0 11 (26.8) 8 (24.2) 3 (37.5) .744
1 20 (48.8) 17 (51.5) 3 (37.5)
2 9 (22) 7 (21.2) 2 (25)
3 1 (2.4) 1 (3) 0 (0)
No. of pregnancies 2 [2e3] 2 [2e3] 2 [1.8e2.5] .73
Primary infection, n (%) 40 (97.6) 33 (100) 7 (87.5) .195
Gestational age at primary infection, wk 10 [7.8e16.2] 11 [8e17] 9 [7.5e9.5] .199
Gestational age at inclusion, wk 25.9 [24.1e31.7] 27 [24.6e31.7] 24.6 [23.8e27.6] .411
Interval between primary infection
and inclusion, wk
16 [12.3e18.6] 15.9 [12.1e18.6] 17.1 [15.9e20] .182
Treatment interruption, n (%) 2/39 (5.1) 1/33 (3) 1/6 (16.7) .287
Duration of treatment, d 89 [41e102] 89 [43e102] 80 [15e97.5] .236
Table 6b.
Fetal characteristics
Total Good outcome Poor outcome
P
Median [interquartile range] Median [interquartile range] Median [interquartile range]
(N ¼ 43) (N ¼ 34) (N ¼ 9)
Inclusion criteria, n (%)
Only 1 symptom at ultrasound 17 (39.5) 15 (44.1) 2 (22.2) .332
Fetal blood DNA load >3000 copies/mL 3 (7) 3 (8.8) 0 (0)
>1 Symptom at ultrasound 23 (53.5) 16 (47.1) 7 (77.8)
Fetal growth restriction, n (%) 3 (7) 1 (2.9) 2 (22.2) .106
Abnormal amount of amniotic fluid, n (%) 3 (7) 2 (5.9) 1 (11.1) .515
Ascites and/or pleural effusion, n (%) 1 (2.3) 1 (2.9) 0 (0) 1
Placentomegaly, n (%) 13 (30.2) 11 (32.4) 2 (22.2) .699
Hyperechogenic bowel, n (%) 25 (58.1) 19 (55.9) 6 (66.7) .712
Hepatomegaly, n (%) 6 (14) 5 (14.7) 1 (11.1) 1
Splenomegaly, n (%) 9 (20.9) 7 (20.6) 2 (22.2) 1
Liver calcifications, n (%) 1 (2.3) 0 (0) 1 (11.1) .209
Moderate cerebral anomalies,a n (%) 5 (11.6) 2 (5.9) 3 (33.3) .054
Fetal viremia at inclusion in log10 IU/mL 4.4 [4e5] 4.3 [3.8e4.8] 5.1 [4.4e5.9] .1
Fetal platelet count at inclusion/mm3 174,000 [145,000e208,000] 177,500 [155,250e208,000] 67,000 [61,000e88,000] .006
a Moderate isolated ventriculomegaly (<15 mm) or isolated cerebral calcification or isolated intraventricular adhesion or vasculopathy of lenticulostriate vessels.
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TABLE 7
Correlation of fetal and neonatal laboratory indicators (viral DNA load and platelet count, from cord blood,
compared with viral DNA load and fetal platelet count obtained in utero before inclusion)
Fetal blood before beginning
maternal treatment Neonatal cord blood Differencesa P
Viral DNA in blood, log10 IU/mL
Median (interquartile range) 4.0 (3.55e4.6) 3.05 (2.57e3.92) e0.5 (e2.075 to e0.075) .01
N 28 32 24
Platelet count/mm3
Median (interquartile range) 173,000 (141,500e201,500) 245,000 (193,000e274,000) 101,000 (47,500e122,000) <.001
N 27 41 27
a Differences between values obtained for same case in utero in fetal blood before maternal treatment and in neonatal cord blood after treatment. Participants with viral DNA load less than threshold
value of 178 IU were considered to have viral DNA load of 89 IU (1.94 IU).
Leruez-Ville et al. In utero treatment of congenital cytomegalovirus infection. Am J Obstet Gynecol 2016.
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1.13 for each 10,000/mm3 decrease in
fetal platelet count <100,000/mm3.4
Another observational study showed
that a fetal platelet count <50,000/mm3
had 80% predictive value for poor
outcome.6 We therefore enrolled women
with either extracerebral or nonsevere
cerebral ultrasound features, a low
platelet count, or a high viral load in
blood sampled in utero.4,6,31 These
criteria were selected speciﬁcally to
target a group at high risk for progressive
damage, on the hypothesis that prenatal
treatment could lower this risk that
could lead to neonatal neuro-
developmental impairment.
According to Simon23 optimal 2-stage
design, high-dosage valacyclovir given
orally to pregnant women was effective
in improving the outcome of pregnan-
cies with a fetus infected with symp-
tomatic CMV, shown by either
extracerebral or nonsevere cerebral ul-
trasound features or abnormal fetal lab-
oratory results. Moreover, when
compared with a historical cohort of
similar cases collected from the litera-
ture,10,24,25,32,33 an unbiased estimation
conﬁrmed the efﬁcacy of valacyclovir
compared to no treatment. Among
the 43 symptomatic fetuses treated in
utero, there were only 4 cases with an
indisputably poor outcome (2 termina-
tions of pregnancy for severe brain
abnormalities and 2 cases of bilateral
hearing loss), while the other 5 infants
symptomatic at birth showed only milddisease (3 with unilateral hearing loss,
1 with isolated thrombocytopenia, and
another with growth restriction). The
clinical impact of valacyclovir may be
explained by its direct inhibition of CMV
replication. In renal transplantation and
in HIV infection, high-dose regimens of
valacyclovir are effective in preventing
CMV disease and suppressing CMV
viremia.16,34,35 A sort of placebo effect
may have also participated in the effect of
valacyclovir. That is, although the par-
ticipants were informed that the efﬁcacy
of valacyclovir in utero was unknown
and that they could request a termina-
tion of pregnancy in accordance with
French law, only 2 terminations were
requested, both after fetuses developed
severe cerebral symptoms visible on ul-
trasound. The availability of treatment
may have alleviated parental anxiety and
dissuaded women from requesting
termination of pregnancy by offering
them something more than helpless
anxiety and expectant management.
Although the valacyclovir dosage used
in this study was much higher than that
used for treatment of herpes simplex
infection in pregnancy (8 g per day vs 1 g
per day), the maternal clinical and
laboratory tolerances were excellent and
no adverse effect was observed in the
neonates.
Moreover, despite the burden of taking
16 tablets throughout the day, cumula-
tive adherence to treatment was >90%.
Overall, 40% of the women met
the inclusion criterion of 1 ultrasoundOCTOBER 2016 Ameriabnormality suggestive of CMV, 53%
had >1, and 7% had only a high fetal
blood viral load (>3000 copies/mL). The
latter criterion was selected on the basis
of previous work by Boppana et al,31 who
reported that no neonates with a viral
load <3000 copies developed hearing
loss. However, a more recent study
reports that fetal viral load >30,000
copies/mL is a predictivemarker for poor
outcome.6 Therefore, the cut-off of 3000
copies/mL might have been too low.
Nonetheless, only 3 cases were included
based on this criterion alone, and 2 of
them had much higher viral loads
(110,000 and 90,000 copies/mL). None
of these 3 patients had a poor outcome.
At birth, viral loads in cord blood were
signiﬁcantly lower and platelet counts
signiﬁcantly higher than in fetal blood
obtained in utero before treatment
began. The antiviral effects of valacy-
clovir can easily explain these changes.
Nonetheless, both differences might also
be due either to chance or the natural
course of these markers since little is
known about the spontaneous kinetics
of blood viral loads or platelet counts
over time after acute fetal infection. The
similarity of blood viral DNA loads re-
ported in neonates born to untreated
mothers, regardless of the trimester of
pregnancy of her primary infection,36
suggests that no spontaneous change in
viral load is likely to be signiﬁcant over
the few weeks of intrauterine life. Post-
natal decreases in viral load have been
evaluated over a much longer periodcan Journal of Obstetrics& Gynecology 462.e8
Original Research OBSTETRICS ajog.orgof time.37 Another reason for the dif-
ferences in the prenatal and postnatal
courses evolutions of viremia is the
closed intrauterine circuit across the
fetal-placental circulation. Moreover,
the 1.0 log reduction we observed in
blood viral load between fetal blood
sampled before treatment and cord
blood at birth after antiviral treatment is
similar to the 1.3 log reduction reported
in a controlled trial of HIV-infected
patients also treated with high-dose
valacyclovir.34 We observed no correla-
tion between the duration of fetal
infection and neonatal platelet counts or
viral loads. Although platelet counts are
reported to increase during pregnancy,
their increase in our study was correlated
with the duration of valacyclovir treat-
ment and was signiﬁcantly higher than
expected in a population of noninfected
fetuses (17). A spontaneous decrease in
fetal viral loads and an increase in
platelet counts over time, independently
of treatment, is very unlikely.
Blood viral load levels have been
reported to be signiﬁcantly higher in
symptomatic neonates.31,38,39 In our
study viral loads in neonatal blood and in
neonatal urine showed only a trend to
being higher in the symptomatic group.
This could be due to the small number of
symptomatic cases in the study (N ¼ 7),
which may not allow reaching statistical
signiﬁcance. One could also speculate
that this gap in viral load levels between
symptomatic and asymptomatic neo-
nates during the natural history of the
infection might have been reduced in a
population of treated fetuses.
The main limitation of our study is
that it is not randomized. It therefore
remains difﬁcult to assess deﬁnitively the
respective roles of true antiviral effect
and a placebo effect to explain the posi-
tive effect of treatment demonstrated
in this setting. However, conducting
a randomized placebo-controlled trial
in pregnant women with a symptomatic
CMV-infected fetus proved utterly
impracticable. This difﬁculty has previ-
ously been encountered for another rare
fetal condition carrying a risk of death or
severe handicap.40 This is especially
relevant for women who choose not to
terminate the pregnancy, at least as long462.e9 American Journal of Obstetrics& Gynecolas a potential good outcome may exist.
Because a classic randomized controlled
trial proved to be too difﬁcult to achieve,
a possibility to strengthen the results of
the present study could be to follow the
design described by Relton et al41 of a
cohort multiple randomized controlled
trial. In such trial, half of the eligible
patients would be randomly selected
to be treated while the other half
would receive usual care; this would
allow keeping comparable arms while
avoiding the unacceptability of classic
randomization. n
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